EbookNetworking
🔍 Search Books
Home
›
Authors
›
Tamra Sami
Books by Tamra Sami
16 books
📄 Lite AMP version
Full site ›
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Canada aims for 7-day approval for Phase I trials; rules redefine sponsors.(Canada): An article from: Bioresearch Monitoring Alert
Tamra Sami
5.95
View Details ›
AAI lacked validation data, evades 483.(Human drugs): An article from: Validation Times
Tamra Sami
5.95
View Details ›
Batelle receives 483 for inadequate maintenance of facility, procedural issues in GLP inspection. (Sponsor-monitors/GLP).(Batelle Memorial Institute, ... An article from: Bioresearch Monitoring Alert
Tamra Sami
5.95
View Details ›
Documentation issues follow Florida investigator from NIH. (Sponsor-monitors/GLP).(National Institutes of Health, University of Florida; assays for drug): An article from: Bioresearch Monitoring Alert
Tamra Sami
5.95
View Details ›
Study coordinator complaint triggers four-month audit, resulting in 12-page 483. (Clinical investigators).: An article from: Bioresearch Monitoring Alert
Tamra Sami
5.95
View Details ›
OHRP reviews 100 cases a year, but fewer than eight go anywhere. (IRBs).: An article from: Bioresearch Monitoring Alert
Tamra Sami
5.95
View Details ›
IRB kept sloppy records, failed to review critical information.(IRBs)(Huntsville Hospital)(Institutional Review Board ): An article from: Bioresearch Monitoring Alert
Tamra Sami
5.95
View Details ›
EU GCP directive to go into force in May despite gaps in member states.(International)(good clinical practice)(European Union): An article from: Bioresearch Monitoring Alert
Tamra Sami
5.95
View Details ›
IVD exporter caught with 'cat in the bag,' as FDA warns firm about rodent control, QS deficiencies.(Medical devices): An article from: Validation Times
Tamra Sami
5.95
View Details ›
GCP inspections to be nation-based; pharma firms advised to 'get it right first time' for Phase I trials.(EU Clinical trials)(Good Clinical Practices): An article from: Bioresearch Monitoring Alert
Tamra Sami
5.95
View Details ›
FDA not eyeing third party audits of raw materials; stressing C of As.(Excipients): An article from: Validation Times
Tamra Sami
5.95
View Details ›
Expecting unexpected AEs can reduce IRB reporting burden; FDA not inclined to expand DMCs to help out.(Adverse events)(Institutional Review ... An article from: Bioresearch Monitoring Alert
Tamra Sami
5.95
View Details ›
Subpart C on prisoner research should be scrapped, SACHRP told.(United States. Office for Human Research Protections. Secretary's Advisory Committee ... An article from: Bioresearch Monitoring Alert
Tamra Sami
5.95
View Details ›
OTC manufacturer changes product specs following validation.(Human drugs): An article from: Validation Times
Tamra Sami
5.95
View Details ›
FDA can find no objections in CI audit. (Clinical investigators).(Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio; clinical investigator, ... article from: Bioresearch Monitoring Alert
Tamra Sami
5.95
View Details ›
FDA to pilot dispute resolution, giving 10 days to challenge 483s.: An article from: Inspection Monitor
Tamra Sami
5.95
View Details ›
